Pb2139 Impact of Overweight in Treatment With Daratumumab in Multiple Myeloma Patients

Abstract

commencing treatment. Three patients (21.4%) relapsed with median time to relapse of 3.6 years. 15 patients (34.9%) achieved complete response after 30 days of commencing therapy and 5 patients (33.3%) relapsed with median time of 2 years. Five patients achieved very good partial response (VGPR), six patients with limited or no response. Summary/Conclusion: Renal disease is the most common presentation of AL amyloidosis followed by cardiac involvement. 2/3 of patients have elevated serum free lambda light chain and most of them have either MGUS or smouldering myeloma on bone marrow biopsy. Diagnoses are mostly made on renal biopsy but rectal biopsy seems to be sensitive for diagnosis of amyloidosis infiltration as well. Bortezomib based therapy appeared to be effective treatment as first line therapy with 79% achieving good haematological response with sustainable remission status. Ongoing follow up and larger cohort will be required for more conclusive results.

Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction

“…A retrospective analysis reported by Rogue et al revealed no significant difference regarding overall survival and adverse events among 9 (39.1%) of 23 myeloma patients with overweight and others. 7 Our patient weighed 115 kg and had a BMI of 51 kg/ m2, which classified her as a myeloma patient with morbid obesity. Unfortunately, detailed safety data are not available for myeloma patients with overweight and obesity who are treated with daratumumab.…”

“…A retrospective analysis reported by Rogue et al revealed no significant difference regarding overall survival and adverse events among 9 (39.1%) of 23 myeloma patients with overweight and others. 7…”